Duncan-Williams Has Buy On Endo Pharmaceuticals Holdings

Duncan-Williams has a Buy rating and a $51 price target on shares of Endo Pharmaceuticals Holdings, Inc.

. In a note to clients, Duncan-Williams writes, "We updated our model to include 3Q11 and 13 days of AMS sales in June. We also converted our therapeutic models from IMS to Wolters Kluwer Pharma Solutions. Our assumptions incorporate stronger growth in both the topical and oral pain market, longer persistence of Voltaren gel (we now model a generic in September) continued growth of Lidoderm until 2014 (we still believe in a delayed settlement with Watson), and slightly more aggressive growth of Fortesta." Shares of ENDP gained 79 cents yesterday to close at $39.80, a gain of 2.03%.